Molecular Profiling of Gynecologic Cancers for Treatment and Management of Disease – Demonstrating Clinical Significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants

Gynecologic cancers are the leading cause of cancer deaths in women worldwide, with annual diagnoses and deaths estimated at 90,000 and 30,000 in the United States, respectively [1]. Gynecologic cancers arise from similar cell/embryonic origins and share a variety of characteristics, but they are also unique in their own ways [2,3,4]. Five types of gynecologic cancers – cervical, ovarian, uterine, vaginal, vulvar – represent the vast majority of cases [5]. Ovarian cancer is the eighth most common cancer diagnosed and accounts for 5% of cancer deaths among women in the US, more than any other gynecologic cancer [6,7].

Source: Cancer Genetics and Cytogenetics - January 13, 2020 Category: Genetics & Stem Cells Authors: Qian Nie, Gregory Omerza, Harshpreet Chandok, Matthew Prego, Meng-Chang Hsiao, Bridgette Meyers, Andrew Hesse, Jasmina Uvalic, Melissa Soucy, Daniel Bergeron, Michael Peracchio, Shelbi Burns, Kevin Kelly, Shannon Rowe, Jens Rueter, Honey V Reddi Source Type: research